🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,041 results for “Advanced” Clear

  1. ZIO-101-C (Darinaparsin)

    Alaunos Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  2. ZIO-101-C (Darinaparsin)

    Alaunos Therapeutics

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  3. ZIO-201

    Alaunos Therapeutics

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  4. ZIO-201-T and doxorubicin

    Alaunos Therapeutics

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  5. [14C]-BMS986504 Mass Balance Study in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  6. [177Lu]Lu-XT117

    The First People's Hospital of Lianyungang

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  7. [^14C]-alisertib

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  8. alisertib

    Takeda

    Advanced Malignancies

    phase 1 small molecule completed

    2 trials

  9. darinaparsin

    Alaunos Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  10. indibulin

    Alaunos Therapeutics

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  11. olaparib

    United Therapeutics Europe Ltd

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  12. oral palifosfamide tris

    Alaunos Therapeutics

    Advanced Cancer

    phase 1 small molecule on hold

    1 trial

  13. palifosfamide-tris

    Alaunos Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  14. zanzalintinib

    Arcus Biosciences

    Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

    phase 1 small molecule terminated

    1 trial

  15. zimberelimab

    Arcus Biosciences

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  16. „INSIGHT“ An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors

    The George Institute

    Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)

    phase 1 other active

    1 trial

  17. CAPECITABINE, CALCIUM FOLINATE, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, FLUOROURACIL, Lenvatinib, Lenvatinib, Calciumfolinat-GRY® 100 mg/10 ml Injektionslösung, OXALIPLATIN, Lenvatinib, CALCIUM LEVOFOLINATE , CAPECITABINE

    Merck Sharp and Dohme

    Advanced/Metastatic Gastroesophageal Adenocarcinoma

    approved small molecule active

    1 trial

  18. Cisplatin Accord Healthcare 1 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Locally advanced head and neck squamous cell carcinoma

    approved small molecule active

    1 trial

  19. Enhanced dermatologic management

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC (Advanced Non-small Cell Lung Cancer)

    approved other active

    1 trial

  20. GAVRETO ®(pralsetinib) capsules

    RIGEL PHARMACEUTICALS INC

    Patients with advanced or metastatic solid tumors

    approved small molecule active

    1 trial

  21. GEMCITABINE HYDROCHLORIDE, CISPLATIN, AVELUMAB, CISPLATIN, CISPLATIN, CISPLATIN, CARBOPLATIN, CARBOPLATIN, GEMCITABINE HYDROCHLORIDE

    Fondazione Telethon ETS

    metastatic or locally advanced urothelial cancer

    approved small molecule active

    1 trial

  22. IMFINZI 50 mg/mL concentrate for solution for infusion., Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    AstraZeneca

    Advanced or recurrent endometrial cancer

    approved small molecule active

    1 trial

  23. LENVATINIB, NIVOLUMAB, CABOZANTINIB, LENVATINIB, NIVOLUMAB, AXITINIB, CABOZANTINIB, PEMBROLIZUMAB, IPILIMUMAB, AXITINIB, AXITINIB

    Fondazione Telethon ETS

    metastatic or locally advanced renal cell carcinoma

    approved small molecule active

    1 trial

  24. LETROZOLE, RIBOCICLIB, GOSERELIN ACETATE, LEE011, TAMOXIFEN

    Novartis Pharmaceuticals

    HR+, HER2- advanced or metastatic breast cancer

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources